Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Neuroscience, Oncology, Rare Diseases and Gastroenterology. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. For more information, visit https://www.takeda.com
Attention-deficit hyperactivity disorder (ADHD) is a diverse condition characterised by symptoms of inattention, hyperactivity and impulsivity; and can have a significant impact on patients’ lives. 1,2 This website provides educational resources intended for healthcare professionals outside the
US and UK with an interest in ADHD. It aims to share scientific advances in ADHD research and provide expert opinions and medical knowledge to support the healthcare professional community.
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 2013.
2. World Health Organization. ICD-11: International Classification of Diseases 11th Revision. 2018. Available at: https://icd.who.int. Accessed January 2021.
Please register now to access these online presentations and then follow the prompts on the screen to select those you would like to view:
Registration conditions differ internationally. Healthcare professionals should refer to full prescribing information from their home country.
Information shown on this page is for healthcare professionals outside of the US only.
Copyright © 2021 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited, used under license.
C-APROM/INT/ELVS/0009 April 2021